Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...
CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...
BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs
Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...
MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...
Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator
Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...
China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply
The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...
BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...
Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion
EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...
CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...
Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
Ant Insurance Reports 23% Surge in Health Insurance Payouts, Processing 4.69 Million Claims in 2023
Ant Insurance, a platform integrated within Alibaba’s Alipay app, reported a 23% year-on-year increase in...
Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support
Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding...
Huadong Medicine’s Relmapirazin Approval Filing Accepted by NMPA for GFR Measurement
Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval...
Lepu Medical Secures NMPA Approval for Innovative Coronary Intravascular Impact Waveguide Tube
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a China-based provider of cardiovascular disease solutions,...
CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...